MedTrace Logo

Tongxinluo Capsule in Ischemic Stroke Patients（TISS)

NCT01919671 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2007

Last updated 2017-01-04

No results posted yet for this study

Summary

The purpose of this study is to assess the effects in improving life self-care ability of stroke patients after taking Tongxinluo Capsule(within 72 hours after onset) versus Placebos for 90 days.

Conditions

Interventions

DRUG

Tongxinluo capsule

for 90 days

DRUG

placebo capsule

for 90 days

Sponsors & Collaborators

  • yongjun wang

    lead OTHER_GOV

Principal Investigators

  • Yongjun Wang, professor · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-10-31
Completion
2016-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01919671 on ClinicalTrials.gov